scholarly journals Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials

2020 ◽  
Vol 22 (5) ◽  
pp. 834-844 ◽  
Author(s):  
Xavier Rossello ◽  
João Pedro Ferreira ◽  
Stuart J. Pocock ◽  
John J.V. McMurray ◽  
Scott D. Solomon ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Sex Differences ◽  
Receptor Antagonist ◽  
Mineralocorticoid Receptor ◽  
Pooled Analysis ◽  
Mineralocorticoid Receptor Antagonist

scholarly journals Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF

2021 ◽  
Vol 9 (1) ◽  
pp. 13-24
Author(s):  
Karola S. Jering ◽  
Faiez Zannad ◽  
Brian Claggett ◽  
Finnian R. Mc Causland ◽  
João Pedro Ferreira ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Mineralocorticoid Receptor ◽  
Mineralocorticoid Receptor Antagonist ◽  
Renal Outcomes

scholarly journals The Mineralocorticoid Receptor Antagonist Eplerenone Suppress Interstitial Fibrosis in Subcutaneous Adipose Tissue in Type 2 Diabetes Patients

2020 ◽  
Author(s):  
Ada Admin ◽  
Marie Louise Johansen ◽  
Jaime Ibarrola ◽  
Amaya Fernández-Celis ◽  
Morten Schou ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Receptor Antagonist ◽  
Subcutaneous Adipose Tissue ◽  
Mineralocorticoid Receptor ◽  
Prostaglandin D2 ◽  
Type I ◽  
Mineralocorticoid Receptor Antagonist ◽  
Subcutaneous Adipose

Activation of the mineralocorticoid receptor (MR) may promote dysfunctional adipose tissue in patients with type 2 diabetes, where increased pericellular fibrosis has emerged as a major contributor. The knowledge of the association between the MR, fibrosis and the effects of an MR antagonist (MRA) in human adipocytes remains very limited. The present sub-study including 30 participants was prespecified as part of the Mineralocorticoid Receptor Antagonist in type 2 Diabetes (MIRAD) trial, randomizing patients to either high dose eplerenone or placebo for 26 weeks. In adipose tissue biopsies, changes in fibrosis were evaluated by immunohistological examinations and by the expression of mRNA and protein markers of fibrosis. Treatment with an MRA reduced pericellular fibrosis, synthesis of the major subunits of collagen type I and VI, and the profibrotic factor α-smooth muscle actin, as compared to placebo in subcutaneous adipose tissue. Furthermore, we found decreased expression of the MR and downstream molecules neutrophil gelatinase–associated lipocalin, galectin-3, and lipocalin-like prostaglandin D2 synthase with an MRA. In conclusions, we present original data demonstrating reduced fibrosis in adipose tissue with inhibition of the MR, which could be a potential therapeutic approach to prevent the extracellular matrix remodeling of adipose tissue in type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document